Advances in the use of iron-chelating agents for the treatment of iron overload.
D000293:Adolescent; D000328:Adult; D000740:Anemia / Q000150:complications; D002648:Child; D002675:Child, Preschool; D003676:Deferoxamine / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005293:Ferritins / Q000097:blood; D006321:Heart / Q000033:anatomy & histology; D006432:Hemochromatosis / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007273:Injections, Intramuscular; D007279:Injections, Subcutaneous; D007408:Intestinal Absorption; D007501:Iron / Q000009:adverse effects* / Q000097:blood / Q000652:urine; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D008099:Liver / Q000033:anatomy & histology / Q000378:metabolism; D008297:Male; D009929:Organ Size; D013789:Thalassemia / Q000628:therapy; D065227:Transfusion Reaction
D007502:Iron Chelating Agents; D005293:Ferritins; D007501:Iron; D003676:Deferoxamine